In the BioHarmony Drug Report Database
Ozenoxacin
Xepi (ozenoxacin) is a small molecule pharmaceutical. Ozenoxacin was first approved as Xepi on 2017-12-11. It is used to treat impetigo in the USA. Xepi’s patents are valid until 2032-01-29 (FDA).
Trade Name
|
Xepi |
|---|---|
Common Name
|
ozenoxacin |
ChEMBL ID
|
CHEMBL3990047 |
Indication
|
impetigo |
Drug Class
|
Antibacterials (quinolone derivatives) |
Image (chem structure or protein)